£10,000 invested in AstraZeneca shares 1 year ago is now worth…
Itâs up 15.6% so £10,000 invested in AstraZeneca (LSE:AZN) shares one year ago, would now be worth approximately £11,560. Clearly, this isnât a bad return for investors who would have also received around £240 in the form of dividends.
Whatâs behind the rise?
AstraZenecaâs share price surge is attributed to its robust financial performance, particularly in 2024, where total revenue and core earnings per share (EPS) grew by 21% and 19%, respectively. The companyâs oncology segment led the charge with a 24% revenue increase. Other areas like cardiovascular and respiratory therapies also contributed to growth.
However, itâs not been a gentle rise. The stock has dipped on several occasions, particularly in late 2024 due to challenges in China. The arrest of AstraZenecaâs country president and other executives, coupled with a probe into alleged illegal data collection, led to sales falling in the region. This caused a temporary decline in the share price.
More broadly, the companyâs long-term potential is a big plus for investors. The company aims to deliver $80bn in total revenue by the end of the decade, up from $54bn, driving improved earnings during the period. Moreover, AstraZenecaâs focus and positioning on oncology is undoubtedly a strategic strength, as the company continues to advance innovative treatments that address critical unmet needs in cancer care.
Dig deeper and it looks undervalued
Despite the China issue â which may have limited financial repercussions but could harm its in-country reputation â many analysts view AstraZeneca as undervalued. Morgan Stanley recently initiated coverage with an Overweight rating, citing the stock as a “compelling entry point” due to its strong pipeline and exposure to high-value markets like oncology, cardiovascular/renal treatments, and next-generation immuno-oncology. The bank anticipates double-digit bottom-line (net income or profit) expansion in 2025, driven by key drugs such as Imfinzi, Enhertu, and Teszpire.
From a valuation perspective, AstraZeneca may appear more expensive than some of its mega-cap pharma peers. For example, its forward price-to-earnings (P/E) ratio of 17.5 times is far high than Pfizer at 8.6 times. However, itâs a different picture when we use growth-adjusted metrics. AstraZenecaâs strong growth projections lead us to a price-to-earnings-to-growth (PEG) ratio of 1.3 versus Pfizerâs 3.3. More broadly, this PEG ratio represents a 23% discount to the healthcare sector average.
The bottom line
AstraZenecaâs revenue aim is reliant on the company launching 20 new medicines and investing in disruptive innovation and sustainable practices. Yet things are never straightforward in pharma and biotech. In fact, companies can spend billions only to achieve trial data that doesnât show a significant improvement against the benchmark treatment. This introduces a degree of risk for investors.
Nonetheless, with a robust pipeline and strong portfolio, Iâm backing AstraZeneca to succeed over the long run. Simply, Iâm considering adding to my position, which is mainly in my SIPP, and leaving it for a decade. There may be ups and downs, but its focus on oncology and investments in disruptive innovations are long-term drivers.
The post £10,000 invested in AstraZeneca shares 1 year ago is now worth⦠appeared first on The Motley Fool UK.
But there are other promising opportunities in the stock market right now. In fact, here are:
5 stocks for trying to build wealth after 50
The cost of living crisis shows no signs of slowing… the conflict in the Middle East and Ukraine shows no sign of resolution, while the global economy could be teetering on the brink of recession.
Whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times. Yet despite the stock market’s recent gains, we think many shares still trade at a discount to their true value.
Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…
We’re sharing the names in a special FREE investing report that you can download today. We believe these stocks could be a great fit for any well-diversified portfolio with the goal of building wealth in your 50’s.
More reading
James Fox has positions in AstraZeneca Plc. The Motley Fool UK has recommended AstraZeneca Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
